Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK, XenoPort Get Complete Response Letter for RLS Drug | Contract Pharma

What are you searching for?

Sign in

GSK, XenoPort Get Complete Response Letter for RLS Drug

GlaxoSmithKline and XenoPort, Inc. received a Complete Response letter from the FDA regarding the NDA for Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of Restless Legs Syndrome (RLS).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and XenoPort, Inc. received a Complete Response letter from the FDA regarding the NDA for Horizant (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). The NDA was submitted to the FDA on January 9, 2009.

The letter states that a preclinical finding of pancreatic acinar cell tumors in rats was a concern and that the FDA can’t approve the drug for RLS at this time. The FDA acknowledged that similar findings were known for gabapentin for refractory epilepsy, but concluded that the seriousness and severity of refractory epilepsy justified the potential risks. The companies are assessing the appropriate next steps and will be communicating with FDA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters